A Single Arm, Phase II Study of the Anti-Blys Monoclonal Antibody, Belimumab in Symptomatic Waldenstroms Macroglobulinaemia.
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Belimumab (Primary)
- Indications Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- 23 Nov 2012 Trial association and lead centre changed from Human Genome Sciences to GlaxoSmithKline as Human Genome Sciences is acquired by GlaxoSmithKline.
- 14 Jun 2010 New trial record